CytomX Therapeutics
CTMX
126 hedge funds and large institutions have $249M invested in CytomX Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 43 increasing their positions, 51 reducing their positions, and 15 closing their positions.
2.45% more ownership
Funds ownership: 79.76% → 82.21% (+2.4%)
2% more capital invested
Capital invested by funds: $243M → $249M (+$5.62M)
3% less funds holding
Funds holding: 130 → 126 (-4)
16% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 51
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$14.4M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.46M |
| 3 |
Morgan Stanley
New York
|
+$2.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.58M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$2.3M |
| 2 |
BlackRock
New York
|
-$2.15M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$1.85M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.76M |
| 5 |
Renaissance Technologies
New York
|
-$1.72M |
CTMX Hedge Fund Activity: Q4 2020 in Review
126 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2020, worth a combined $249M — up 2.3% from $243M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CTMX and 11 opened new positions — a net loss of 4 holders — while 51 trimmed existing stakes and 43 added.
The largest buyer was BVF Inc, adding an estimated $14.4M. The largest seller was First Manhattan, exiting entirely with an estimated $2.3M sold.
- 126 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2020, down from 130 in Q3 2020.
- Funds reported $249M of CytomX Therapeutics stock for Q4 2020, up 2.3% quarter-over-quarter.
- 11 funds opened new CytomX Therapeutics positions in Q4 2020 and 15 closed out, a net change of -4 holders.
- The largest CytomX Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $14.4M added.
- The largest CytomX Therapeutics seller in Q4 2020 was First Manhattan, an estimated $2.3M sold.
Based on aggregated 13F filings for Q4 2020.